Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Mass Detector

By Drug Discovery Trends Editor | October 7, 2013

Waters Corporation introduced the Waters Acquity QDa detector, which is designed to bring high-quality, mass spectral data to chromatographic separations. 
 
Designed as a synergistic component of a chromatographic system, the Acquity QDa detector is compatible with Waters Acquity UltraPerformance LC (UPLC), Acquity UltraPerformance Convergence Chromatography (UPC2), Alliance high-performance liquid chromatography (HPLC) and Waters supercritical fluid chromatography (SFC) and LC-based purification systems.
 
The Acquity QDa detector addresses the barriers of complexity, size and cost that have hindered the adoption of mass spectrometry for everyday use. It is purposefully designed for analytical scientists who need mass spectral data without the complexity of a mass spectrometer. With the on/off simplicity that analytical scientists have long wanted from mass spectrometry, the the system fully automates sample analysis and eliminates sample-specific adjustments for certainty in sample results, from user to user and system to system. Robust and reliable enough for routine use, the detector generates the high-quality mass spectral data expected of a single quadrupole mass spectrometer in a mass detector no bigger than a familiar photodiode array (PDA) detector.  
 
The Acquity QDa detector complements optical detection, such as the PDA detector, by confirming the identity of compounds with mass spectral information. Additionally, the detector extends the limits of sample detection for a chromatographic separation by quantifying compounds having no UV response or that are present at levels not detectable and quantifiable by optical detection.  By simplifying laboratory workflows, the detector enhances the value of every analysis and increases productivity by eliminating the need to run additional assays or turn to time-consuming alternative techniques in order to establish with certainty the levels and identity of specific sample compounds.
 
The Acquity QDa detector is available now for separations systems running Empower 2 & 3 Chromatography Data System (CDS) software, including enterprise deployment with automated qualification. Empower 3 makes mass and UV spectral data processing as integrated as the separations systems they were acquired on. The Acquity QDa detector is also available now for MassLynx 4.1 mass spectrometry software.
 
 
Date: October 7, 2013
Source: Waters Corporation

Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE